In this first-in-human phase 1 study, SY-5007, a highly selective and potent RET inhibitor, demonstrated a manageable safety profile and promising anti-tumor efficacy in 122 patients with advanced solid tumors harboring activating RET alterations. Here, RET is linked to neoplasm.